Breast Cancer Chemosensitivity
|
Email this
Print this
Dihua Yu
This book is co-published with Springer.
Please click here to purchase this book at the Springer site. ISBN: 978-0-387-74037-9 Pub date: 2007-08-30 190 pages 15 figures 9 tables 2 color pages |
About this bookBreast cancer is the most common cancer and the second leading cause of cancer death in American women. Despite advances in early detection and the improved understanding of the molecular basis of breast cancer biology, about 30% of patients with early-stage breast cancer have recurrent disease and need effective systemic treatment. Cytotoxic chemotherapies, hormonal therapies, and immunotherapeutic agents are used in the adjuvant, neoadjuvant, and metastatic setting. Systemic agents are generally active at the beginning of therapy in the majority of breast cancers. However, progression occurs after a variable period of time when resistance to therapy develops. In this book, a group of world leading experts review critical aspects of resistance to systemic therapy in breast cancer patients. |
|
Table of contents1. Overview of Resistance to Systemic Therapy in Patients with Breast Cancer 2. Roles of Multidrug Resistance Genes in Breast Cancer Chemoresistance 3. Therapy-Induced Apoptosis in Primary Tumors 4. Cell Cycle Deregulation in Breast Cancer: Insurmountable Chemoresistance
5. p53, BRCA1 and Breast Cancer Chemoresistance 6. Integrin-Mediated Adhesion: Tipping the Balance between Chemosensitivity
7. Insulin-Like Growth Factors and Breast Cancer Therapy 8. EGF Receptor in Breast Cancer Chemoresistance 9. Molecular Mechanisms of ErbB2-Mediated Breast Cancer Chemoresistance 10. Estrogen Receptors in Resistance to Hormone Therapy 11. Novel Approaches for Chemosensitization of Breast Cancer Cells: |
|